Biofilm Formation and Antifungal Resistance in Candida Species
1 other identifier
observational
300
0 countries
N/A
Brief Summary
- 1.To determine the susceptibility pattern of our local isolated Candida strains which is essential for optimal management of fungal infection.
- 2.Detection of biofilm formation by conventional and molecular methods
- 3.Comparison between C. albicans and non-albicans in the prevalence of biofilm formation and biofilm -forming genes
- 4.Find the association between antifungal resistance and biofilm formation in candida strains isolated from patients
- 5.Determination of clinical factors associated with occurrence of infections.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2025
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 2, 2025
CompletedFirst Posted
Study publicly available on registry
November 24, 2025
CompletedStudy Start
First participant enrolled
December 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 20, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 12, 2026
November 24, 2025
November 1, 2025
9 months
October 2, 2025
November 17, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
To asses the prevalence of candida species as a cause of infection in patient in hematology intinsive care unit
1 year
To asses the prevalence of genes responsible for biofilm formation in different candida species
1 year
Eligibility Criteria
patients admitted to hematology intensive care
You may qualify if:
- Eligible participants in the study were those with invasive infection and had one or more of this criteria :
- oSuppressed general body immunity.
- oSuppressed local body immunity as a result of trauma or invasive procedures.
- oResistant to antibiotic therapy.
- oNegative samples for bacterial examination and culture.
- Critical life threatening infect
You may not qualify if:
- Patients who received antifungal therapy within 3 days prior to sample collection.
- Resistant to antibiotic therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
sputum,urine and blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- demonstrator at microbiology department at Assiut university
Study Record Dates
First Submitted
October 2, 2025
First Posted
November 24, 2025
Study Start
December 20, 2025
Primary Completion (Estimated)
September 20, 2026
Study Completion (Estimated)
October 12, 2026
Last Updated
November 24, 2025
Record last verified: 2025-11